183 related articles for article (PubMed ID: 12382089)
1. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management.
Hirsch HH; Battegay M
Infection; 2002 Oct; 30(5):293-8. PubMed ID: 12382089
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV Infection and its therapies.
Wohl DA
Top HIV Med; 2004; 12(3):89-93. PubMed ID: 15310940
[TBL] [Abstract][Full Text] [Related]
3. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
[TBL] [Abstract][Full Text] [Related]
4. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
[TBL] [Abstract][Full Text] [Related]
5. HIV-associated lipodystrophy syndrome.
Milinković A
Coll Antropol; 2006 Dec; 30 Suppl 2():59-62. PubMed ID: 17508476
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
Feleke Y; Fekade D; Mezegebu Y
Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
[TBL] [Abstract][Full Text] [Related]
8. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
Calza L; Manfredi R; Pocaterra D; Chiodo F
J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
[TBL] [Abstract][Full Text] [Related]
9. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity.
ter Hofstede HJ; Burger DM; Koopmans PP
Neth J Med; 2003 Dec; 61(12):393-403. PubMed ID: 15025414
[No Abstract] [Full Text] [Related]
11. [No improvement of lipodystrophy syndrome in an HIV-infected patient].
Lanzafame M; Faggian F; Lattuada E; Antolini D; Concia E
Recenti Prog Med; 2004 Jun; 95(6):312-3. PubMed ID: 15248414
[TBL] [Abstract][Full Text] [Related]
12. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
Calza L; Manfredi R; Chiodo F
Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
[TBL] [Abstract][Full Text] [Related]
13. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
[TBL] [Abstract][Full Text] [Related]
14. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.
Cazanave C; Dupon M; Lavignolle-Aurillac V; Barthe N; Lawson-Ayayi S; Mehsen N; Mercié P; Morlat P; Thiébaut R; Dabis F;
AIDS; 2008 Jan; 22(3):395-402. PubMed ID: 18195566
[TBL] [Abstract][Full Text] [Related]
15. [Lipodystrophy in HIV infected children].
Popielska J
Pol Merkur Lekarski; 2008 May; 24(143):408-13. PubMed ID: 18634383
[TBL] [Abstract][Full Text] [Related]
16. Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy.
Bickel M; Zangos S; Lutz T; Eisen J; Knecht G; Goebel FD; Crespi CM; Jacobi V; Staszewski S; Klauke S
Scand J Infect Dis; 2008; 40(1):36-9. PubMed ID: 17852925
[TBL] [Abstract][Full Text] [Related]
17. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
[TBL] [Abstract][Full Text] [Related]
18. [Lipodystrophy syndrome. Therapeutic progress is still pending].
Weber K; Heiken H; Stoll M; Schmidt RE; Behrens G
MMW Fortschr Med; 2003 Apr; 145 Spec No 1():28-32. PubMed ID: 15011581
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing the development of lipodystrophy in human immunodeficiency virus-infected patients.
Collazos J; Rodriguez-Guardado A; Maradona JA; Mayo J; Asensi V; Ibarra S; Carton JA; Casado L
Scand J Infect Dis; 2003; 35(5):339-40. PubMed ID: 12875524
[TBL] [Abstract][Full Text] [Related]
20. Low effectiveness of highly active antiretroviral therapy and high mortality in the Greenland HIV-infected population.
Lohse N; Ladefoged K; Pedersen L; Jensen-Fangel S; Sørensen HT; Obel N
Scand J Infect Dis; 2004; 36(10):738-42. PubMed ID: 15513400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
